(Editor-in-Chief, Nephrology Dialysis Transplantation); Ron T. Gansevoort, The Netherlands; Ali G. Gharavi, USA; John S. Gill, Canada (Deputy Editor, American Journal of Transplantation); Eddie L. Greene, USA (Associate Editor, Diabetes Care); Brenda R. Hemmelgarn, Canada; Matthias Kretzler, USA; Mark Lambie, UK (Editorial Board Member, Peritoneal Dialysis International); Pascale H. Lane, USA (Co-Chair, ASN Media and Communications Committee); Joseph Laycock, UK (Managing Editor, Pediatric Nephrology); Shari Leventhal, USA; Michael Mittelman, USA (International Patient Advisor, The BMJ); Patricia Morrissey, USA (Executive Managing Editor, Kidney International); Cynthia D. Mulrow, USA; Marlies Ostermann, UK (Section Editor, Journal of Critical Care & Blood Purification); Jaya K. Rao, USA; Lesley Rees, UK (Co-Editor, Pediatric Nephrology); Pierre Ronco, France (Editor, Kidney International); Franz Schaefer, Germany; Jennifer St. Clair Russell, USA; Caroline Vinck, Belgium (Managing Editor, Nephrology Dialysis Transplantation); Stephen B. Walsh, UK; and Daniel E. Weiner, USA (Editor-in-Chief, Kidney Medicine). KDIGO staff Michael Cheung, John Davis, Amy Earley, and Tanya Green. DISCLOSURE ASL declared having received research support from AstraZeneca, National Institute of Diabetes and Digestive and Kidney Diseases, and National Kidney Foundation. K-UE declared having received consultancy fees from Akebia, Bayer, and Genzyme; speaker honoraria from Bayer and Vifor; and research support from Amgen, AstraZeneca, Bayer, Fresenius Medical Care, and Genzyme. NMD declared having equity ownership/stock options from Eli Lilly & Co. RM declared having received consultancy fees from Baxter Healthcare. PMP declared having received consultancy fees from Baxter Healthcare and GE Healthcare. JPB declared having received consultancy fees from Verily Scientific Advisory Board. JSB declared having received consultancy fees from Natera and research support from Angion, CareDx, Natera, National Institutes of Health, and Novartis. HIF declared having received consultancy fees from National Kidney Foundation and research support from National Institutes of Health. DF declared having received consultancy fees from Fresenius Kabi, Sanofi, and Vifor; speaker honoraria from Fresenius Kabi, Sanofi, and Vifor; and research support from Fresenius Medical Care. JSG declared having received consultancy fees from Sanofi and research support from Astellas. BRH declared having received research support from Canadian Institutes of Health Research. MK declared having received consultancy fees from Boehringer Ingelheim and Certa; future consultancy fees from Gilead Sciences and Goldfinch Bio; and KDIGO conference report AS Levey et al.: KDIGO nomenclature for kidney function and disease 1128 Kidney International (2020) 97, 1117–1129 research support from Angion, AstraZeneca, Boehringer Ingelheim, ChanZuckerberg Initiative, Eli Lilly & Co, Elpidera, European Union Innovative Medicine Initiative, Foundation for the National Institutes of Health, Gilead, Goldfinch Bio, Janssen, JDRF, National Institutes of Health, and Novo Nordisk. ML declared having received speaker honoraria from Fresenius Medical Care and research support from Baxter Healthcare. MO declared having received consultancy fees from bioMérieux and NxStage; speaker honoraria from Baxter Healthcare and Fresenius Medical Care; and research support from Fresenius Medical Care and LaJolla Pharma. LR declared having received consultancy fees from GSK and speaker honoraria from Vitaflo. JSCR declared having received research support from Patient-Centered Outcomes Research Institute. DEW declared having received consultancy fees from Akebia, Janssen Biopharmaceuticals, and Tricida. MJ declared having received consultancy fees from Astellas, AstraZeneca, GSK, MSD, and Vifor Fresenius Medical Care Renal Pharma; speaker honoraria from Abbvie, Amgen, Menarini, MSD, and Vifor Fresenius Medical Care Renal Pharma; travel support from Amgen; and research support from Alexion, Amgen, Janssen-Cilag, Otsuka, and Roche. WCW declared having received consultancy fees from Akebia, AMAG, Amgen, AstraZeneca, Bayer, Daiichi-Sankyo, Relypsa, and ZS Pharma; speaker honoraria from FibroGen; and research support from National Institutes of Health. All the other authors declared no competing interests. ACKNOWLEDGMENTS The conference was sponsored by Kidney Disease: Improving Global Outcomes (KDIGO) and supported in part by unrestricted educational grants from AstraZeneca, Bayer HealthCare, Boehringer Ingelheim, Fresenius Medical Care, Roche, and Sanofi. The content of this article does not necessarily reflect the views or opinions of the organizations or journals that were represented at the conference. Responsibility for the information and views expressed is limited to the coauthors. The authors are grateful to Juhi Chaudhari, MPH, at Tufts Medical Center, Boston, MA, for assistance with manuscript preparation, and to Kidney Disease: Improving Global Outcomes (KDIGO) staff members John Davis, Amy Earley, Tanya Green, and Melissa Thompson for assistance with the meeting and manuscript. SUPPLEMENTARY MATERIAL Supplementary File (PDF) Table S1. KDIGO definitions and classifications of kidney diseases.